These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 25356865)

  • 1. Triggering necroptosis in cisplatin and IAP antagonist-resistant ovarian carcinoma.
    McCabe KE; Bacos K; Lu D; Delaney JR; Axelrod J; Potter MD; Vamos M; Wong V; Cosford ND; Xiang R; Stupack DG
    Cell Death Dis; 2014 Oct; 5(10):e1496. PubMed ID: 25356865
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Smac mimetic triggers necroptosis in pancreatic carcinoma cells when caspase activation is blocked.
    Hannes S; Abhari BA; Fulda S
    Cancer Lett; 2016 Sep; 380(1):31-8. PubMed ID: 27267809
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination of IAP antagonist and IFNγ activates novel caspase-10- and RIPK1-dependent cell death pathways.
    Tanzer MC; Khan N; Rickard JA; Etemadi N; Lalaoui N; Spall SK; Hildebrand JM; Segal D; Miasari M; Chau D; Wong WL; McKinlay M; Chunduru SK; Benetatos CA; Condon SM; Vince JE; Herold MJ; Silke J
    Cell Death Differ; 2017 Mar; 24(3):481-491. PubMed ID: 28106882
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activity of protein kinase RIPK3 determines whether cells die by necroptosis or apoptosis.
    Newton K; Dugger DL; Wickliffe KE; Kapoor N; de Almagro MC; Vucic D; Komuves L; Ferrando RE; French DM; Webster J; Roose-Girma M; Warming S; Dixit VM
    Science; 2014 Mar; 343(6177):1357-60. PubMed ID: 24557836
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cellular IAP proteins and LUBAC differentially regulate necrosome-associated RIP1 ubiquitination.
    de Almagro MC; Goncharov T; Newton K; Vucic D
    Cell Death Dis; 2015 Jun; 6(6):e1800. PubMed ID: 26111062
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Absence of RIPK3 predicts necroptosis resistance in malignant melanoma.
    Geserick P; Wang J; Schilling R; Horn S; Harris PA; Bertin J; Gough PJ; Feoktistova M; Leverkus M
    Cell Death Dis; 2015 Sep; 6(9):e1884. PubMed ID: 26355347
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Critical contribution of oxidative stress to TNFα-induced necroptosis downstream of RIPK1 activation.
    Shindo R; Kakehashi H; Okumura K; Kumagai Y; Nakano H
    Biochem Biophys Res Commun; 2013 Jun; 436(2):212-6. PubMed ID: 23727581
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dasatinib promotes paclitaxel-induced necroptosis in lung adenocarcinoma with phosphorylated caspase-8 by c-Src.
    Diao Y; Ma X; Min W; Lin S; Kang H; Dai Z; Wang X; Zhao Y
    Cancer Lett; 2016 Aug; 379(1):12-23. PubMed ID: 27195913
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RIPK1 and RIPK3: critical regulators of inflammation and cell death.
    Newton K
    Trends Cell Biol; 2015 Jun; 25(6):347-53. PubMed ID: 25662614
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neoalbaconol induces cell death through necroptosis by regulating RIPK-dependent autocrine TNFα and ROS production.
    Yu X; Deng Q; Li W; Xiao L; Luo X; Liu X; Yang L; Peng S; Ding Z; Feng T; Zhou J; Fan J; Bode AM; Dong Z; Liu J; Cao Y
    Oncotarget; 2015 Feb; 6(4):1995-2008. PubMed ID: 25575821
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RIPK1 can function as an inhibitor rather than an initiator of RIPK3-dependent necroptosis.
    Kearney CJ; Cullen SP; Clancy D; Martin SJ
    FEBS J; 2014 Nov; 281(21):4921-34. PubMed ID: 25195660
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RIPK1 inhibits ZBP1-driven necroptosis during development.
    Newton K; Wickliffe KE; Maltzman A; Dugger DL; Strasser A; Pham VC; Lill JR; Roose-Girma M; Warming S; Solon M; Ngu H; Webster JD; Dixit VM
    Nature; 2016 Dec; 540(7631):129-133. PubMed ID: 27819682
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential roles of RIPK1 and RIPK3 in TNF-induced necroptosis and chemotherapeutic agent-induced cell death.
    Moriwaki K; Bertin J; Gough PJ; Orlowski GM; Chan FK
    Cell Death Dis; 2015 Feb; 6(2):e1636. PubMed ID: 25675296
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Receptor interactive protein kinase 3 promotes Cisplatin-triggered necrosis in apoptosis-resistant esophageal squamous cell carcinoma cells.
    Xu Y; Lin Z; Zhao N; Zhou L; Liu F; Cichacz Z; Zhang L; Zhan Q; Zhao X
    PLoS One; 2014; 9(6):e100127. PubMed ID: 24959694
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic targeting of necroptosis by Smac mimetic bypasses apoptosis resistance in acute myeloid leukemia cells.
    Safferthal C; Rohde K; Fulda S
    Oncogene; 2017 Mar; 36(11):1487-1502. PubMed ID: 27869161
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IAP antagonists sensitize murine osteosarcoma cells to killing by TNFα.
    Shekhar TM; Miles MA; Gupte A; Taylor S; Tascone B; Walkley CR; Hawkins CJ
    Oncotarget; 2016 Jun; 7(23):33866-86. PubMed ID: 27129149
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Berberine in combination with cisplatin induces necroptosis and apoptosis in ovarian cancer cells.
    Liu L; Fan J; Ai G; Liu J; Luo N; Li C; Cheng Z
    Biol Res; 2019 Jul; 52(1):37. PubMed ID: 31319879
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Bcr-Abl inhibitor GNF-7 inhibits necroptosis and ameliorates acute kidney injury by targeting RIPK1 and RIPK3 kinases.
    Qin X; Hu L; Shi SN; Chen X; Zhuang C; Zhang W; Jitkaew S; Pang X; Yu J; Tan YX; Wang HY; Cai Z
    Biochem Pharmacol; 2020 Jul; 177():113947. PubMed ID: 32247850
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RIPK3 promotes cell death and NLRP3 inflammasome activation in the absence of MLKL.
    Lawlor KE; Khan N; Mildenhall A; Gerlic M; Croker BA; D'Cruz AA; Hall C; Kaur Spall S; Anderton H; Masters SL; Rashidi M; Wicks IP; Alexander WS; Mitsuuchi Y; Benetatos CA; Condon SM; Wong WW; Silke J; Vaux DL; Vince JE
    Nat Commun; 2015 Feb; 6():6282. PubMed ID: 25693118
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mdm2 antagonists induce apoptosis and synergize with cisplatin overcoming chemoresistance in TP53 wild-type ovarian cancer cells.
    Mir R; Tortosa A; Martinez-Soler F; Vidal A; Condom E; Pérez-Perarnau A; Ruiz-Larroya T; Gil J; Giménez-Bonafé P
    Int J Cancer; 2013 Apr; 132(7):1525-36. PubMed ID: 22961628
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.